Our study of node negative, ER+/HER2- breast cancer patients with low RS (<18) observed extremely low rates of LRR: 0.9% (13/1396) in the whole cohort and 0.7% (8/1184) in patients treated with endocrine therapy alone. This evidence concerns the gene ERBB2 and breast cancer.